Exchange: NASDAQ·Updated 07:30 PM EST

PTGX News

News
all
press releases
Protagonist Therapeutics (NASDAQ:PTGX) Stock Rating Lowered by Zacks Research
Zacks Research cut shares of Protagonist Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Thursday...
MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Stock Rating Lowered by Zacks Research
Zacks Research cut shares of Protagonist Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Thursday...
MarketBeat
More News
Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) has been assigned a consensus rating of "Buy" from the seventeen ratings firms that are currently covering the company, Marketbeat reports. Sixteen research analysts have rated the stock with a buy rating and one has given a strong buy r...
MarketBeat
Stephens Investment Management Group LLC lifted its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 66.2% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 468,502 shares of the company's stock after purchasin...
MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) insider Arturo Molina sold 2,718 shares of Protagonist Therapeutics stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $124.65, for a total value of $338,798.70. Following the...
MarketBeat
JNJ's rally reflects stronger earnings and promising drug launches, but MedTech weakness, patent losses and litigation risks remain.
Zacks
The average of price targets set by Wall Street analysts indicates a potential upside of 37.6% in Protagonist Therapeutics (PTGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of +18.99% and +2.77%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Niagen Bioscience (NAGE) delivered earnings and revenue surprises of 0.00% and -9.81%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks

Advertisement|Remove ads.